» Articles » PMID: 38486369

Use of Proton Pump Inhibitors is Associated with Increased Risk of Out-of-hospital Cardiac Arrest in the General Population: a Nested Case-control Study

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Proton pump inhibitors (PPIs) impair cardiac repolarization, prolong the QT interval, and may potentially be pro-arrhythmic. However, the risk of out-of-hospital cardiac arrest (OHCA) is scarcely investigated. We studied whether past or current PPI use is associated with OHCA in the general population.

Methods And Results: We conducted a nationwide nested case-control study with OHCA-cases of presumed cardiac causes and age/sex/OHCA-date-matched non-OHCA-controls from the general population. Exposure to PPI was categorized into three mutually exclusive groups of current-, past-, and non-use. Conditional logistic regression analyses with adjustments for risk factors of OHCA were used to calculate the odds ratio (OR) of OHCA comparing PPI use with non-users. We identified 46 578 OHCA cases and 232 890 matched non-OHCA controls (mean: 71 years, 68.8% men). PPI was used by 8769 OHCA-cases and 21 898 non-OHCA controls, and current use of PPI was associated with increased odds of OHCA compared with non-users [OR: 1.32 (95% CI: 1.28-1.37)], while past use conferred no increase in the odds of OHCA [OR: 1.01 (95% CI: 0.98-1.04)]. This increased odds of OHCA occurred in both sexes. Finally, the ORs remained elevated when we repeated the analyses in individuals without registered ischaemic heart disease [OR: 1.36 (95% CI: 1.31-1.41)], without heart failure [OR: 1.33 (95% CI: 1.29-1.38)], or without any cardiovascular comorbidities [OR: 1.84 (95% CI: 1.70-2.00)]. Also, the OR remained elevated when H2-antagonists served as the reference group [OR: 1.28 (95% CI: 1.11-1.47)].

Conclusion: PPI use is associated with an increased risk of OHCA in the general population. Considering the widespread use of PPIs, this study raises concerns and the need for awareness to balance the benefit and risk of treatment.

Citing Articles

Pro-arrhythmic potential of proton-pump inhibitors.

Lazzerini P, Accioli R, Capecchi P, Acampa M Nat Rev Cardiol. 2024; .

PMID: 39653788 DOI: 10.1038/s41569-024-01107-w.


Proton pump inhibitors and cardiovascular risk: a critical review.

Duarte G, Lopez J, Sosa F, Molina G, Shaban M, Mark J Future Cardiol. 2024; 20(14):779-794.

PMID: 39466134 PMC: 11622795. DOI: 10.1080/14796678.2024.2412910.


Impact of proton pump inhibitor use on clinical outcomes in East Asian patients receiving clopidogrel following drug-eluting stent implantation.

Kim J, Hong S, Cha J, Lim S, Joo H, Park J BMC Med. 2024; 22(1):335.

PMID: 39148087 PMC: 11328459. DOI: 10.1186/s12916-024-03549-y.

References
1.
Hvid-Jensen F, Nielsen R, Pedersen L, Funch-Jensen P, Drewes A, Larsen F . Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting. Clin Epidemiol. 2013; 5:493-9. PMC: 3857010. DOI: 10.2147/CLEP.S49354. View

2.
Othman F, Card T, Crooks C . Proton pump inhibitor prescribing patterns in the UK: a primary care database study. Pharmacoepidemiol Drug Saf. 2016; 25(9):1079-87. DOI: 10.1002/pds.4043. View

3.
Straus S, Sturkenboom M, Bleumink G, Dieleman J, van der Lei J, de Graeff P . Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005; 26(19):2007-12. DOI: 10.1093/eurheartj/ehi312. View

4.
Fan W, Liu H, Shen Y, Hong K . The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients. Cardiovasc Drugs Ther. 2023; 38(3):517-525. DOI: 10.1007/s10557-023-07425-4. View

5.
Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z . Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019; 365:l1580. PMC: 6538974. DOI: 10.1136/bmj.l1580. View